Article Information
History
- June 26, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Rossana Bussani1,*,
- Edoardo Schneider2,
- Lorena Zentilin2,
- Chiara Collesi1,2,
- Hashim Ali3,
- Luca Braga2,3,
- Ilaria Secco3,
- Maria Concetta Volpe2,
- Andrea Colliva2,
- Fabrizio Zanconati1,
- Giorgio Berlot1,
- Furio Silvestri1,
- Serena Zacchigna1,2,*,+ and
- Mauro Giacca1,2,3,*,+
- 1Department of Medical, Surgical and Health Sciences, University of Trieste, 34127 Trieste, Italy
- 2International Centre for Genetic Engineering and Biotechnology (ICGEB), 34149 Trieste, Italy
- 3King’s College London, British Heart Foundation Centre of Research Excellence, School of Cardiovascular Medicine & Sciences, SE5 9NULondon, United Kingdom
- ↵+Address for correspondence: Mauro Giacca, MD PhD, King’s College London, School of Cardiovascular Medicine & Sciences, Email: mauro.giacca{at}kcl.ac.uk, Serena Zacchigna, MD PhD, ICGEB, Cardiovascular Biology Laboratory, Email: zacchign{at}icgeb.org
↵* These authors equally contributed as senior authors
Posted June 26, 2020.
Persistence of viral RNA, widespread thrombosis and abnormal cellular syncytia are hallmarks of COVID-19 lung pathology
